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Objectives This study sought to test the hypothesis that colchicine treatment after percutaneous coronary intervention (PCI)
can lead to a decrease in in-stent restenosis (ISR).
Background ISR rates are particularly high in certain patient subsets, including diabetic patients, especially when a bare-
metal stent (BMS) is used. Pharmacological interventions to decrease ISR could be of clinical relevance.
Methods Diabetic patients with contraindication to a drug-eluting stent, undergoing PCI with a BMS, were randomized to
receive colchicine 0.5 mg twice daily or placebo for 6 months. Restenosis and neointima formation were studied
with angiography and intravascular ultrasound 6 months after the index PCI.
Results A total of 196 patients (63.6  7.0 years of age, 128 male) were available for analysis. The angiographic ISR
rate was 16% in the colchicine group and 33% in the control group (p  0.007; odds ratio: 0.38, 95% confi-
dence interval: 0.18 to 0.79). The number needed to treat to avoid 1 case of angiographic ISR was 6 (95% confi-
dence interval: 3.4 to 18.7). The results were similar for IVUS-defined ISR (odds ratio: 0.42; 95% confidence in-
terval: 0.22 to 0.81; number needed to treat  5). Lumen area loss was 1.6 mm2 (interquartile range: 1.0 to
2.9 mm2) in colchicine-treated patients and 2.9 mm2 (interquartile range: 1.4 to 4.8 mm2) in the control group
(p  0.002). Treatment-related adverse events were largely limited to gastrointestinal symptoms.
Conclusions Colchicine is associated with less neointimal hyperplasia and a decreased ISR rate when administered to dia-
betic patients after PCI with a BMS. This observation may prove useful in patients undergoing PCI in whom im-
plantation of a drug-eluting stent is contraindicated or undesirable. (J Am Coll Cardiol 2013;61:1679–85)
© 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.055Implantation of coronary stents after angioplasty has led to
significant decreases in clinical events compared with plain
balloon angioplasty (1,2). However, restenosis has been a
considerable problem with bare-metal stents (BMS), which
prompted the advent of drug-eluting stents. Their principal
function is to inhibit in-stent neointima formation, thus
decreasing restenosis rates (3).
The problem of restenosis appears to be more severe in
certain subsets of coronary artery disease patients, including
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2012, accepted January 2, 2013.those with diabetes, in whom some of the first BMS trials
restenosis rates exceeded 50% (4). As a result, drug-eluting
stents are particularly beneficial in these patients, in terms of
angiographic outcomes and target lesion revascularization
(5). However, there are diabetic patients undergoing percu-
taneous coronary intervention (PCI) who have important
contraindications to implantation of drug-eluting stents,
including patients with planned necessary surgery as well as
those who need anticoagulation treatment, in whom triple
antithrombotic therapy (double antiplatelet and 1 anticoag-
ulant) is associated with a high risk of bleeding and should
be as short term as possible (6).
See page 1686
Colchicine is an old drug with known anti-inflammatory
and antiproliferative actions. Both of these effects could
conceivably interfere with the formation of neointima in
coronary stents, thus reducing the rate of in-stent restenosis
f
a
a
a
s
a
a
S
w
m
i
P
a
f
m
C
(
l
w
O
a
1680 Deftereos et al. JACC Vol. 61, No. 16, 2013
Colchicine and Restenosis April 23, 2013:1679–85(ISR). In addition, it has been
shown to be safe in different
subsets of patients with cardio-
vascular disease (7,8). The aim of
the present study was to study
the effect of 6 months of treat-
ment with oral colchicine on
neointima formation and reste-
nosis in diabetic patients undergo-
ing PCI with BMS implantation.
Methods
Population. This was a double-
blind,prospective,placebo-controlled
study. Eligible patients were dia-
betic, 40 to 80 years of age, under-
going PCI in a coronary artery with
a diameter of at least 2.5 mm with a BMS. Acceptable reasons
for not implanting a drug-eluting stent were: contraindica-
tion to long-term dual antiplatelet treatment, need for triple
antithrombotic therapy, planned or high probability of
necessary surgery in the following 12 months, or the
patient’s expressed wish in the context of the PCI informed
consent procedure. Only 1 lesion per patient was included in
the study. (If PCI was performed in 1 coronary site in a
patient, the site with the greater artery diameter was
included.) Diabetes mellitus had to be previously diagnosed
by a specialist, with the patient treated with either oral
medication or insulin. Exclusion criteria were left main
artery disease (30% in angiography); PCI performed as
primary treatment for ST-segment elevation myocardial
infarction, hepatic impairment (Child-Pugh class B or C);
target vessel segment presenting particular technical chal-
lenges for intravascular ultrasound (IVUS) (e.g., marked
tortuosity, vessel with steep take-off angle); severe or end-
stage renal failure (estimated glomerular filtration rate 20
ml/min/1.73 m2 or requiring dialysis); history of intolerance
to colchicine, myopathy, and statin hepatotoxicity or myo-
toxicity; women with child-bearing potential; and inability
or unwillingness to adhere to standard treatment or to
provide consent. The protocol was approved by the institu-
tional review boards. All patients provided informed
consent.
Procedures. Patients underwent baseline coronary angiog-
raphy and PCI, with IVUS evaluation of the implanted
BMS. All stents were post-dilated with an appropriately
sized noncompliant balloon. All stents were evaluated im-
mediately after implantation with IVUS to obtain baseline
measurements. Immediate post-implantation IVUS images
were also used to optimize stent expansion and apposition
and to identify significant edge dissections or significant
residual plaque burden at stent edges, whereupon comple-
mentary corrective action was undertaken (e.g., further
post-dilation or additional stenting), if deemed appropriate
Abbreviations
and Acronyms
angio-ISR  angiographic
in-stent restenosis
BMS  bare-metal stent(s)
CI  confidence interval
ISR  in-stent restenosis
IVUS  intravascular
ultrasound
IVUS-ISR  intravascular
ultrasound-defined in-stent
restenosis rate
MLA  minimum lumen
area
PCI  percutaneous
coronary interventionby the operator. (It was determined by the review board who wapproved of the study protocol that it would not be ethical
to disregard IVUS findings, although routine post-PCI
IVUS-guided stent evaluation does not reflect current clin-
ical practice.) Angiographic and IVUS follow-up was per-
formed 6 months after the index PCI.
Angiographic vessel and lesion parameters were measured
using quantitative coronary angiography software (Xcelera,
Philips Healthcare, Eindhoven, the Netherlands). Late
lumen loss was defined as the difference between the
baseline in-stent minimum luminal diameter and the min-
imum luminal diameter on follow-up angiography. Angio-
graphic ISR (angio-ISR) was defined as presence of 50%
in-stent stenosis at the 6-month follow-up.
IVUS was performed after intracoronary administration
of 0.3 to 0.5 mg of nitroglycerin. A digital IVUS catheter
(Eagle Eye Gold, Volcano Corp., Rancho Cordova, Cali-
fornia) was introduced into the target vessel and a pull back
was performed through the implanted stent, with a motor-
ized automatic pull back system (Track Back II, Volcano
Corp.) at a constant speed of 0.5 mm/s. Additional pull
backs were performed to ensure adequate quality of captured
images. Captured IVUS data, identified only by a serial
number, were analyzed offline. Each recorded pull back loop
was inspected by formally trained IVUS operators who
made manual corrections to the automated border delinea-
tion applied by the system software. Volumetric data were
then automatically calculated. Neointima volume was cal-
culated as stent minus lumen volume and divided by the
stent length in millimeters to account for different stent
lengths (normalized neointima volume). The percentage of
neointimal volume was defined as in-stent neointimal vol-
ume divided by stent volume. In-stent minimum lumen area
(MLA) was measured and recorded. IVUS-defined ISR
(IVUS-ISR) was defined as in-stent MLA of 4 mm2 at
ollow-up (a cutoff used in past studies [9]). In-stent lumen
rea loss was calculated as post-PCI MLA minus the MLA
t follow-up. A subset of the pull backs (20%) were
nalyzed twice, unbeknown to the reviewers. The intraob-
erver correlation index was 0.93 for lumen measurements
nd 0.91 for volumes. All IVUS pull backs were analyzed at
core laboratory.
tudy treatments and adverse event monitoring. Patients
ere randomized to receive colchicine or placebo for 6
onths. Colchicine was administered from the day of the
ndex PCI (within 24 h) at a dose of 0.5 mg twice daily.
atients were followed with clinic visits until follow-up
ngiography at 6 months. Monitoring of adverse events
ocused on gastrointestinal manifestations, hepatotoxicity,
yelotoxicity/hematotoxicity, myotoxicity, and alopecia.
omplete blood counts and standard biochemical analyses
glucose, urea, creatinine, liver enzymes, creatine kinase,
actate dehydrogenase) were performed at 2, 4, 8, 16, and 24
eeks after the index PCI.
utcome measures. The main outcome measures were
ngio-ISR and IVUS-ISR. Secondary outcome measures
ere angiographic and IVUS parameters of lumen loss and
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April 23, 2013:1679–85 Colchicine and Restenosisin-stent neointimal hyperplasia, including late lumen loss
(angiography), lumen area loss, percentage of neointima
volume, and normalized neointima volume (IVUS).
Statistical analysis. Assuming a 40% rate of ISR in the
control group, a sample size of 81 per group (in a 1:1
allocation ratio) would be required to have a probability of
80% to detect a 50% reduction in ISR, at an alpha level of
0.05. All patients who received at least 1 dose of study
treatment were included in the analysis. Continuous vari-
ables were expressed as mean SD and compared using the
Student t test, if their distribution did not deviate significantly
rom the normal distribution (tested with the Kolmogorov-
mirnov test). If a significant deviation from the normal
istribution was found, continuous variables were expressed as
edian (interquartile range) and compared using nonparamet-
ic tests (Mann-Whitney U and Wilcoxon for unpaired and
aired comparisons, respectively; all variables summarized as
edian and interquartile range were analyzed with nonpara-
etric methods). Categorical variables were expressed as per-
Figure 1 Study Flow Chart
Of 222 randomized patients, 196 were available for analysis.entages and counts and compared using the chi-square test orFisher exact test if the produced matrices contained cells with
an expected value 5. Odds ratios were calculated using the
Mantel-Haenszel procedure. SPSS software package version
17 was used (SPSS Inc., Chicago, Illinois). Values of p 0.05
(2 sided) were considered indicative of statistical significance,
with the exception of the 2 coprimary endpoints: to adjust for
using 2 primary null hypotheses, we used the Sidak-Bonferroni
formula to correct the expected type I error. The adjusted alpha
level was thus calculated to be 0.025, and p values  0.025
were considered statistically significant in the case of the two
main outcome measures (angio-IVUS and IVUS-ISR).
Results
Study flow and population characteristics. Of 222 eligi-
ble patients who consented to take part in the study, 26
were not available for follow-up catheterization. As a
result, 196 (100 in the colchicine and 96 in the placebo
group) completed the study procedures and were available
for analysis (Fig. 1). The 2 treatment arms were well
corona
ction; R
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Colchicine and Restenosis April 23, 2013:1679–85balanced with similar epidemiological and clinical back-
ground (Table 1).
Outcome measures. The rate of angio-ISR in the total of
196 patients was 24% at 6 months (the severity of angio-
graphic restenosis was overall moderate in the whole cohort,
with the majority of patients with restenosis falling in the
50% to 70% stenosis severity range) (Table 2), with a
significant difference between the 2 treatment arms: the
angio-ISR rate was 52% lower in the colchicine group
compared with the control group (Fig. 2). The odds ratio
for colchicine-treated patients to have ISR on follow-up was
0.38 (95% confidence interval [CI]: 0.18 to 0.79). The
number needed to treat with colchicine to avoid 1 case of
angio-ISR was 6 (95% CI: 3.4 to 18.7).
Patient CharacteristicsTable 1 Patient Characteristics
Feature Overall (N  196) Colc
Epidemiological background
Age, yrs 63.6 7.0
Male 128 (65)
BMI, kg/m2 27.4 3.9
Smoking 74 (38)
Hypertension 95 (49)
Diabetes 196 (100)
Insulin-treated 53 (27)
Family history of CAD 81 (41)
Renal dysfunction 65 (33)
LVEF, % 55.6 6.8
Clinical presentation
Stable CAD 135 (69)
ACS 61 (31)
Procedure-related parameters
Lesion site
LAD 106 (54)
LCx 38 (19)
RCA 52 (27)
No. of stents 1 (1–2)
Total stent length, mm 24 (18–32)
Stent diameter, mm 3.0 (3.0–3.5)
CTOs 24 (12)
Values are mean  SD, count (%), or median (interquartile range).
ACS  acute coronary syndrome; BMI  body mass index; CAD 
descending; LCx  left circumflex; LVEF  left ventricular ejection fra
Grades of Stenosis Severity and In-Stent Minimum Lumen Diameteon Follow-Up C ronary Angiography in Patie ts With Restenosis (NTable 2 Grades of Sten sis Severity and In-Stent Mi imum Lumon Follow-Up Coronary Angiography in Patients With R
Total (n  48)
N % Cum. %
In-stent stenosis severity, %
50–59 17 35.4 35.4
60–69 15 31.3 66.7
70–79 12 25.0 91.7
80 4 8.3 100.0
Minimum lumen diameter, mm
1.5 2 4.2 4.2
1.0–1.5 33 68.8 72.91.0 13 27.1 100.0The results in terms of IVUS-defined restenosis were
similar (Fig. 2). The IVUS-ISR rate was 33%, with colchicine-
treated patients having a 44% lower probability of IVUS-
ISR at follow-up (odds ratio: 0.42; 95% CI: 0.22 to 0.81).
Five patients had to be treated with colchicine to avoid 1
case of IVUS-ISR (95% CI: 3.2 to 18.1).
Both angiographic and IVUS descriptors of neointima
formation indicated attenuation of neointimal hyperplasia
in the colchicine group compared with the control group
(Table 3). In terms of angiographic follow-up, late lumen
loss in the control group was more than double that in the
active treatment group, resulting in a significantly lower
MLD at follow-up (Fig. 3). IVUS area and volume mea-
surements were along the same lines. In-stent lumen area
Group (n  100) Placebo Group (n  96) p Value
3.7 6.9 63.5 7.2 0.78
3 (63) 65 (68) 0.49
7.4 3.6 27.5 4.3 0.59
6 (36) 38 (40) 0.61
8 (48) 47 (49) 0.89
0 (100) 96 (100) 1.00
9 (29) 24 (25) 0.53
4 (44) 37 (39) 0.44
6 (36) 29 (30) 0.39
5.3 7.4 55.9 6.2 0.51
2 (72) 63 (66)
0.34
8 (28) 33 (34)
4 (54) 52 (54)
8 (18) 20 (21) 0.83
8 (28) 24 (25)
1 (1–2) 1 (1–2) 0.82
4 (18–34) 20 (18–28) 0.81
0 (3.0–3.5) 3.0 (3.0–3.5) 0.46
2 (12) 12 (13) 0.92
ry artery disease; CTO  chronic total occlusion; LAD  left anterior
CA  right coronary artery.
8)iameter
osis (N  48)
Controls (n  32) Colchicine (n  16)
n % Cum. % n % Cum. %
1 34.4 34.4 6 37.5 37.5
2 37.5 71.9 3 18.8 56.3
6 18.8 90.7 6 37.5 93.8
3 9.4 100.0 1 6.3 100.0
1 3.1 3.1 1 6.3 6.3
3 71.9 75.0 10 62.5 68.8hicine
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April 23, 2013:1679–85 Colchicine and Restenosisloss was 1.6 mm2 (interquartile range: 1.0 to 2.9 mm2) in
colchicine-treated patients compared with 2.9 mm2 (inter-
uartile range: 1.4 to 4.8 mm2) in control subjects (p 
.002). In accordance, the percentages of neointima volume
nd normalized neointima volume were 63% and 70%
igher in the control group, respectively (Table 3).
In terms of clinical events, 1 patient in the control group
nd 1 in the active treatment group died during follow-up
Figure 2 Primary Outcome Measures in
the Active Treatment and Control Groups
Angiographic in-stent restenosis (Angio-ISR) rate was significantly lower in the
colchicine group, irrespective of definition (quantitative angiography or intravas-
cular ultrasound [IVUS]).
Angiographic and IVUS Measurements at Baseline and Follow-UpTable 3 Angiographic and IVUS Measurements at Baseline and
Parameter Overall (N  19
Quantitative angiography
Baseline stenosis, % 84 (75–91)
Lesion length, mm 21.3 (15.6–28.4
Proximal reference diameter, mm 3.2 (3.0–3.6)
Distal reference diameter, mm 3.0 (2.8–3.4)
MLD pre-dilation, mm 0.5 (0.3–0.8)
MLD post-stenting, mm 3.1 (2.9–3.5)
MLD follow-up, mm 2.6 (1.6–3.0)
Late lumen loss, mm 0.6 (0.3–1.4)
IVUS
Surface area measurements
Baseline proximal reference MLA, mm2* 8.1 (7.1–9.5)
Baseline distal reference MLA, mm2* 7.5 (6.6–9.0)
Baseline in-stent MLA, mm2 7.1 (6.1–9.0)
Follow-up proximal reference MLA, mm2* 7.3 (6.4–8.7)
Follow-up distal reference MLA, mm2* 6.7 (5.7–8.1)
Follow-up in-stent MLA, mm2 4.9 (2.4–6.9)
Volumetric parameters
Stent volume, mm3 164 (118–230)
In-stent neointima volume, % 25.0 (14.0–52.8
In-stent normalized neointima volume, mm3/mm 1.99 (1.12–3.71Values are median (interquartile range). *The proximal and distal reference segments were 10-mm segm
IVUS  intravascular ultrasound; MLA  minimum lumen area; MLD  minimum lumen diametercauses of death were recorded as acute pulmonary edema
nd stroke, respectively). Nine patients (4 of 112 patients
3.6%] in the colchicine group and 5 of 110 [4.5%] in the
ontrol group) underwent reintervention (defined in the
resent study as PCI of the target lesion or bypass grafting
f the target vessel).
dverse events and treatment discontinuation. Gastro-
ntestinal symptoms (diarrhea and nausea) were the most
ommon adverse events in the colchicine group. Of the
olchicine-treated patients, 16% reported having diarrhea or
ausea versus 7% of those taking placebo (p  0.058).
yalgia and muscle cramps were reported by 15% and 10%
f colchicine-treated patients and the control group, respec-
ively (p 0.336). In one of them, creatine kinase levels rose
igher than 5 times the upper reference limit, returning to
ormal after discontinuation of a statin and colchicine. This
atient had no signs or laboratory findings of rhabdomyol-
sis. No cases of hepatotoxicity or hematotoxicity were
ecorded. Two patients (1 from each treatment arm) re-
orted accelerated hair loss.
Overall, 17 patients in the colchicine group (17%) and 9
atients in the control group (9%) discontinued their study
edication before completing 180 days of treatment (p 
.116). Colchicine-treated patients discontinued treatment
arlier than the control group (mean duration of treatment
mong those who withdrew was 26 days in the colchicine
roup and 47 days in the control group; p  0.03). Late
umen loss was 0.8 mm2 (interquartile range: 0.3 to 1.5 mm2) in
atients in the colchicine group who discontinued treatment
nd 0.3 mm2 (interquartile range: 0.2 to 0.6 mm2) in those
who completed treatment (p  0.025). There was a non-
w-Up
Colchicine (n  100) Placebo (n  96) p Value
84 (75–92) 85 (75–90) 0.94
21.5 (15.6–30.9) 17.9 (15.6–25.6) 0.89
3.2 (3.0–3.6) 3.2 (3.0–3.6) 0.61
3.0 (2.8–3.4) 3.0 (2.8–3.5) 0.76
0.5 (0.3–0.8) 0.5 (0.3–0.8) 0.90
3.1 (2.9–3.5) 3.1 (2.9–3.5) 0.45
2.8 (2.2–3.1) 2.3 (1.3–2.9) 0.01
0.4 (0.2–0.8) 0.9 (0.5–1.8) 0.01
8.1 (7.1–9.7) 8.1 (7.1–9.4) 0.47
7.8 (6.8–9.2) 7.3 (6.4–8.7) 0.11
7.3 (6.2–9.1) 6.8 (6.1–8.7) 0.14
7.5 (6.6–9.1) 7.2 (6.2–8.2) 0.04
7.0 (5.8–8.3) 6.3 (5.5–7.4) 0.02
5.5 (4.0–7.2) 4.2 (1.7–6.3) 0.01
169 (125–252) 158 (111–220) 0.20
20.5 (12.0–35.8) 33.5 (16.8–60.2) 0.01
1.64 (0.95–2.99) 2.79 (1.36–3.96) 0.01Follo
6)
)
)
)ents proximal and distal to the stent edges.
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Colchicine and Restenosis April 23, 2013:1679–85significant trend toward a higher binary angio-ISR rate in
those who discontinued (5 of 17; 29.4%) versus the rest of
the colchicine group (11 of 72; 13.3%) (p  0.141). Among
atients who stayed on treatment until completion of the
tudy, compliance was high, as indicated by pill counts
95.6% of doses were taken by the patients).
atients lost to follow-up. To account for patients who
ere lost to follow-up or refused to undergo follow-up
ngiography, we performed an alternative analysis, with the
ssumption that all 7 patients of the colchicine group had
SR, whereas those 8 of the control group who did not
resent for follow-up angiography had an ISR rate similar
o that of the rest of the control group. The difference in
ngio-ISR rate between the 2 arms remained significant in
his analysis (p  0.048), with an odds ratio of 0.54 (95%
I: 0.29 to 0.99).
iscussion
olchicine was shown in the present study to be associated
ith a significant decrease in ISR at 6 months, when
dministered at a daily dose of 1 mg for 6 months to diabetic
atients undergoing PCI with implantation of a BMS.
eointimal hyperplasia, as indicated by IVUS-derived area
nd volumetric parameters, was markedly attenuated in
atients receiving colchicine. The population included in
he present study is a clinically relevant subset of coronary
rtery disease patients undergoing PCI because the problem
f ISR is especially important for diabetic patients and the
Figure 3 MLD in the Colchicine and Control Groups
Minimum lumen diameter (MLD), as assessed by quantitative angiography,
before the index procedure (percutaneous coronary intervention [PCI]), immedi-
ately after and at follow-up. The horizontal black lines correspond to the
median, the lower edge of the boxes to the 25th percentile and the upper edge
of the boxes to the 75th percentile. The p values correspond to the Mann-Whit-
ney U test for the difference between the 2 groups.se of drug-eluting stents is not always desirable or feasible. tColchicine disrupts the mitotic spindle by inhibiting the
elf-assembly of microtubules (10). It has a potent anti-
nflammatory effect and acts on several cellular components
f the immune process, including neutrophils and macro-
hages, and affects the expression of cytokines (10–12). It
as unique features compared with other available anti-
nflammatory agents, including corticosteroids and non-
teroidal anti-inflammatory drugs (namely, its antimitotic
ffect and the absence of detrimental effects on the cardio-
ascular system). Inflammatory processes play a prominent
art in the molecular mechanisms of restenosis (13–16), and
he centrality of their role remains valid despite modifica-
ions in the cascade model of restenosis proposed by Libby
t al. (13) in 1992.
Colchicine has an antimitotic effect, obviously useful for
reventing a process characterized by cellular hyperplasia, as
ell as an anti-inflammatory effect, which should inhibit the
ery important contribution of inflammation to in-stent
eointima formation, and, on top of that, does not seem to
hare the undesirable properties of other classes of anti-
nflammatory agents that render them unsafe for use in
atients with cardiovascular disease. It appears that colchi-
ine should, in all probability, be beneficial in preventing
estenosis. However, it has been shown that this is not the
ase, at least as far as plain balloon angioplasty is concerned,
s implied by experimental and clinical studies (17–19).
’Keefe et al. (18) studied 197 patients who received either
olchicine 1.2 mg/day or placebo for 6 months after balloon
ngioplasty (without stenting) and found no difference in
he angiographic restenosis rate. However, the mechanism
f restenosis after balloon angioplasty differs in a substantial
ay from the mechanism of ISR. Elastic recoil and arterial
essel remodeling play an important role, in addition to
eointimal hyperplasia, in restenosis after plain angioplasty,
hereas in the case of stenting, lumen loss is almost
xclusively due to neointima formation (20–22). As a
onsequence, because colchicine is unlikely to affect vascular
lastic recoil or remodeling in any perceivable way, it could
e expected to be ineffective in preventing restenosis after
lain balloon angioplasty, while being effective in attenuat-
ng neointimal hyperplasia and, thus, decreasing ISR after
tent implantation.
The revascularization rate of the target lesion was mark-
dly lower than the observed rate of angiographic (or
VUS-defined) restenosis (the revascularization rate in the
hole cohort was almost 4% in 6 months compared with a
4% rate of angio-ISR). This is explained by the fact that a
arge proportion of patients with ISR were asymptomatic.
here are 3 main reasons for that: 1) patients were receiving
arefully observed optimized medical treatment; 2) patients
ere diabetic (in whom silent ischemia is common [23,24]);
nd 3) a considerable percentage (66.7%) of the patients
ith ISR had an angiographic restenosis severity 70%.
The tolerability profile of colchicine was good in the
resent study, without serious adverse events related to
reatment. This is most probably due to the relatively low
11
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April 23, 2013:1679–85 Colchicine and Restenosisdose used (0.5 mg twice daily). This is consistent with the
study by O’Keefe et al. (18), as well as other studies in
different populations of patients with cardiovascular disease
(7,8), in which daily doses of up to 2 mg have been used for
periods ranging from 1 to 6 months.
Study limitations. The endpoints of the present study
were not clinical. More powered studies with longer
follow-up would be needed to demonstrate a clinical benefit
for colchicine use in this setting. As a result, no firm clinical
recommendation can be made on the basis of these findings.
Conclusions
Colchicine is associated with less neointimal hyperplasia
and a reduced ISR rate when administered to diabetic
patients after BMS placement. This observation may
prove to be useful in patients undergoing PCI in whom
implantation of a drug-eluting stent is contraindicated or
undesirable.
Reprint requests and correspondence: Dr. Georgios Giannopou-
los, Cardiology Department, Athens General Hospital “G. Gen-
nimatas,” 154 Mesogeion Avenue, 11527 Athens, Greece. E-mail:
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